Literature DB >> 32410898

Cancer Patient Care during COVID-19.

Amer Harky1, Chun Ming Chiu2, Thomas Ho Lai Yau3, Sheung Heng Daniel Lai4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32410898      PMCID: PMC7221386          DOI: 10.1016/j.ccell.2020.05.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


× No keyword cloud information.

Main Text

Since WHO declared COVID-19 a global pandemic, measures including lockdown, social distancing, and service reprioritization have been imposed to deal with the unprecedented crisis. However, this poses two major health risks for cancer patients: compromised cancer care and their increased vulnerability to COVID-19. In primary care, family physicians reported delays in delivering cancer screening tests and reluctance to refer patients with suspected cancer to secondary care, posing a risk to missing diagnosis (Jones et al., 2020), whereas in specialist units downscaling of cancer care has been reported in many countries, including India, Singapore, and African countries (Pramesh and Badwe, 2020, Vanderpuye et al., 2020). Systemic treatments are withheld due to worries of treatment-induced complications. Curative surgeries could face delays, due to shortage in manpower, medical supplies, and high-dependency care capacities (van de Haar et al., 2020). In light of these challenges, this Letter addresses the issues of COVID-19 in cancer management and possible measures in streamlining future cancer services. To ameliorate the crisis, infection control measures and hospital surveillance have been imposed in various methods (Table S1). Prior to outpatient visits in the U.S., India, and some European countries, patients would be triaged on respiratory symptoms and contact histories. While this was done by telephone calls in Europe (van de Haar et al., 2020), out-of-hospital pods have been used in the U.S. and India to screen outpatients (Pramesh and Badwe, 2020, Ueda et al., 2020). For inpatients, effective infectious control measures like vigorous preadmission surveillance, with regular temperature testing, blood tests, and high-resolution computed tomography (HRCT) of lungs, were reported in China (Wang et al., 2020). Others downscaled their services to only include new referrals that are acute and emergency (Vanderpuye et al., 2020). However, these safety measures would disrupt delivery of cancer care and delay in-patient treatment. Shifting to home deliveries of oral medication to cancer patients’ homes has allowed the continuity of care toward the affected patients (van de Haar et al., 2020). However, this temporary change aims to slow the disease progression until services return to normal once COVID-19 subsides, as well as to reduce risk of treatment-induced complications and unnecessary hospital visits. For oncological surgery, out-of-hours operations have been a viable coping strategy adopted by worldwide cancer centers to catch up on delayed surgeries (Table S1). As of May 2020, lung cancer surgery service in Liverpool have been maintained during the COVID-19 pandemic. In Indonesia, surgery eligibility has been adjusted to prioritize aggressive cancers, post-neoadjuvant cancers, and timetabling surgeries and outpatient to avoid clashes on same days (Brahma, 2020). Although cancer surgery is considered to be essential in the U.S., delays to surgery are being managed by oral therapeutics due to lack of personal protective equipment (Ueda et al., 2020). In order to minimize hospital travel, most healthcare providers have started to transition medical practice to telemedicine (Table S1). Besides replacing outpatient services with virtual calls (Pramesh and Badwe, 2020, van de Haar et al., 2020), in the U.S. healthcare system, automated logic flow bots in emergency departments can refer moderate-high risk patients to direct-to-consumer care. These services can be covered by quarantined doctors to free up other doctors to perform in-person care (Hollander and Carr, 2020). Before this epidemic, tele-oncology has demonstrated similar effectiveness to in-person care at lower costs and has high levels of satisfaction in patients and health professionals (Sirintrapun and Lopez, 2018). Telemedicine can facilitate cancer management by providing remote chemotherapy supervision, symptom management, and palliative care as well as psychological support (Sirintrapun and Lopez, 2018). Thus, we believe that this is a precious opportunity for other centers to trial the integration of telemedicine into cancer care while alleviating the pressures of COVID-19. Departmental adjustments to improve communication and work efficiency have also been made (Table S1). Online channels for communication between staff and webinars at Indian cancer hospitals have been made available to facilitate collective decision making and sharing ideas amidst social distancing (Pramesh and Badwe, 2020). Additional measures to ensure safety of staff includes paid leave given to high-risk staff, such as those with comorbidities, those who are taking immunosuppressive medication, or those who are currently pregnant. Cancer centers have also used telecommunications for multidisciplinary team meetings to implement social distancing (Vanderpuye et al., 2020). Several other countries have employed a segregated team workflow in which staff are separated into teams to avoid an entire department being quarantined if a staff member is infected (Pramesh and Badwe, 2020, Vanderpuye et al., 2020). Overall, the COVID-19 pandemic places stress on standard cancer management pathways, which may compromise all aspects of cancer care and can affect multi-organs (Zaim et al., 2020). In order to maintain a high quality of care for cancer patients, efficacious leadership frameworks shall be crucial to staff morale, communication, and rapid response to incidents. Healthcare providers should prepare for a possible surge in cancer cases, especially when it comes to meeting new demands. We believe implementing telemedicine could offer short-term relief for the current crisis and provide valuable experience in reshaping future practice.
  9 in total

Review 1.  Telemedicine in Cancer Care.

Authors:  S Joseph Sirintrapun; Ana Maria Lopez
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

2.  Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China.

Authors:  Zhijie Wang; Jie Wang; Jie He
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777

3.  Virtually Perfect? Telemedicine for Covid-19.

Authors:  Judd E Hollander; Brendan G Carr
Journal:  N Engl J Med       Date:  2020-03-11       Impact factor: 91.245

Review 4.  Caring for patients with cancer in the COVID-19 era.

Authors:  Joris van de Haar; Louisa R Hoes; Charlotte E Coles; Kenneth Seamon; Stefan Fröhling; Dirk Jäger; Franco Valenza; Filippo de Braud; Luigi De Petris; Jonas Bergh; Ingemar Ernberg; Benjamin Besse; Fabrice Barlesi; Elena Garralda; Alejandro Piris-Giménez; Michael Baumann; Giovanni Apolone; Jean Charles Soria; Josep Tabernero; Carlos Caldas; Emile E Voest
Journal:  Nat Med       Date:  2020-04-16       Impact factor: 53.440

5.  Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal.

Authors:  Masumi Ueda; Renato Martins; Paul C Hendrie; Terry McDonnell; Jennie R Crews; Tracy L Wong; Brittany McCreery; Barbara Jagels; Aaron Crane; David R Byrd; Steven A Pergam; Nancy E Davidson; Catherine Liu; F Marc Stewart
Journal:  J Natl Compr Canc Netw       Date:  2020-03-20       Impact factor: 11.908

6.  Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care.

Authors:  Daniel Jones; Richard D Neal; Sean R G Duffy; Suzanne E Scott; Katriina L Whitaker; Kate Brain
Journal:  Lancet Oncol       Date:  2020-04-30       Impact factor: 41.316

Review 7.  COVID-19 and Multiorgan Response.

Authors:  Sevim Zaim; Jun Heng Chong; Vissagan Sankaranarayanan; Amer Harky
Journal:  Curr Probl Cardiol       Date:  2020-04-28       Impact factor: 5.200

8.  Cancer Management in India during Covid-19.

Authors:  C S Pramesh; Rajendra A Badwe
Journal:  N Engl J Med       Date:  2020-04-28       Impact factor: 91.245

9.  Preparedness for COVID-19 in the oncology community in Africa.

Authors:  Verna Vanderpuye; Moawia Mohammed Ali Elhassan; Hannah Simonds
Journal:  Lancet Oncol       Date:  2020-04-03       Impact factor: 41.316

  9 in total
  17 in total

1.  Relying on serendipity is not enough: Building a resilient health sector in India.

Authors:  Indrani Gupta
Journal:  Indian Econ Rev       Date:  2020-08-19

Review 2.  COVID-19: Unique public health issues facing Black, Asian and minority ethnic communities.

Authors:  Eyad Abuelgasim; Li Jing Saw; Manasi Shirke; Mohamed Zeinah; Amer Harky
Journal:  Curr Probl Cardiol       Date:  2020-05-08       Impact factor: 5.200

3.  Integrative Oncology Consultations Delivered via Telehealth in 2020 and In-Person in 2019: Paradigm Shift During the COVID-19 World Pandemic.

Authors:  Santhosshi Narayanan; Gabriel Lopez; Catherine Powers-James; Bryan M Fellman; Aditi Chunduru; Yisheng Li; Eduardo Bruera; Lorenzo Cohen
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

4.  Rapid Implementation of Telemedicine During the COVID-19 Pandemic: Perspectives and Preferences of Patients with Cancer.

Authors:  Shira Peleg Hasson; Barliz Waissengrin; Eliya Shachar; Marah Hodruj; Rochelle Fayngor; Mirika Brezis; Alla Nikolaevski-Berlin; Sharon Pelles; Tamar Safra; Ravit Geva; Ido Wolf
Journal:  Oncologist       Date:  2021-02-01       Impact factor: 5.837

5.  Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation.

Authors:  Cathy Eng; Emerson Y Chen; Jane Rogers; Mark Lewis; Jonathan Strosberg; Ramya Thota; Smitha Krishnamurthi; Paul Oberstein; Rang Govindarajan; Gary Buchschacher; Sandip Patel; Davendra Sohal; Taymeyah Al-Toubah; Philip Philip; Arvind Dasari; Hagan Kennecke; Stacey Stein
Journal:  JCO Oncol Pract       Date:  2021-02-03

6.  Telemedicine in cardiovascular surgery during COVID-19 pandemic: A systematic review and our experience.

Authors:  Ayomikun Ajibade; Hiba Younas; Mark Pullan; Amer Harky
Journal:  J Card Surg       Date:  2020-08-16       Impact factor: 1.778

7.  Completion rate and impact on physician-patient relationship of video consultations in medical oncology: a randomised controlled open-label trial.

Authors:  Jakob N Kather; Eva C Winkler; Thomas Walle; Erkin Erdal; Leon Mühlsteffen; Hans Martin Singh; Editha Gnutzmann; Barbara Grün; Helene Hofmann; Alexandra Ivanova; Bruno Christian Köhler; Felix Korell; Athanasios Mavratzas; Andreas Mock; Constantin Pixberg; David Schult; Helen Starke; Niels Steinebrunner; Lena Woydack; Andreas Schneeweiss; Mareike Dietrich; Dirk Jäger; Johannes Krisam
Journal:  ESMO Open       Date:  2020-11

8.  The impact of the COVID-19 pandemic on cardiology services.

Authors:  Omar Fersia; Sue Bryant; Rachael Nicholson; Karen McMeeken; Carolyn Brown; Brenda Donaldson; Aaron Jardine; Valerie Grierson; Vanessa Whalen; Alistair Mackay
Journal:  Open Heart       Date:  2020-08

9.  Neurological Manifestations of COVID-19: A systematic review and current update.

Authors:  Abigail Whittaker; Matthew Anson; Amer Harky
Journal:  Acta Neurol Scand       Date:  2020-06-02       Impact factor: 3.915

Review 10.  COVID-19 and Cancer: Current Challenges and Perspectives.

Authors:  Ziad Bakouny; Jessica E Hawley; Toni K Choueiri; Solange Peters; Brian I Rini; Jeremy L Warner; Corrie A Painter
Journal:  Cancer Cell       Date:  2020-10-01       Impact factor: 38.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.